SUR, School of Medicine, Monica E. York, Brock E. Boehm, Gyorgy Petrovics, Gregory Chesnut, and Indu Kohaar, SUR, School of Medicine, Monica E. York, and Brock E. Boehm, Gyorgy Petrovics, Gregory Chesnut, and Indu Kohaar
Germline m (Abstract Number: 2074) DISCLAIMER Monica E York1, Brock E. Boehm2, Gyorgy Petrovics3,4, Gregory Chesnut2,3, Indu Kohaar3,4 1Uniformed Services University of the Health Sciences School of Medicine, Bethesda, MD 20814, USA; 2Urology Service, Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, USA; 3Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20817, USA; 4The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, 20817, USA; The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions or policies of Uniformed Services University of the Health Sciences (USUHS), The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense (DoD), the Departments of the Army, Navy, or Air Force. Mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. ABSTRACT MATERIALS & METHODS Biomarkers of Aggressive Prostate Cancer at Diagnosis: Equally Applicable Among African American and Caucasian Men? RESULTS In the United States, prostate cancer (CaP) remains to be the second leading cause of cancer deaths in men1. CaP is predominantly indolent at diagnosis with a small fraction (25-30%) representing aggressive subtype (Gleason score 7-10), which is prone to metastatic progression. Although several different diagnostic biomarkers are available to clinicians, very few comparative trials have been performed to assess the clinical effectiveness. It is of note however, that many of these clinical trials have been over-represented by men of Caucasian origin even though African American men have a 1.7 higher incidence and 2.1 higher rate of mortality from prostate cancer2. Biomarkers for CaP diagnosis based on the tissue of origin inclu, RITM0022766, In the United States, prostate cancer (CaP) remains to be the second leading cause of cancer deaths in men. CaP is predominantly indolent at diagnosis with a small fraction (25-30%) representing aggressive subtype (Gleason score 7-10), which is prone to metastatic progression. Although several different diagnostic biomarkers are available to clinicians, very few comparative trials have been performed to assess the clinical effectiveness. It is of note however, that many of these clinical trials have been over-represented by men of Caucasian origin even though African American men have a 1.7 higher incidence and 2.1 higher rate of mortality from prostate cancer2. Biomarkers for CaP diagnosis based on the tissue of origin include urine-based gene expression assays (PCA3, Select MDx, ExoDx Prostate IntelliScore, Mi- Prostate Score), blood-based protein biomarkers (4K, PHI) and diagnostic tissue-based molecular biomarkers (Confirm MDx). In this review, we will discuss some of the adjunctive biomarker tests, that are currently available to help clinicians decide which patients are at risk of having high grade prostate cancer on prostate biopsy with the emphasis on clinical utility of the test across African American (AA) and Caucasian (CA) men.